Last reviewed · How we verify
POMx — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
POMx (POMx) — HaEmek Medical Center, Israel. POMx is a pomegranate extract-based therapeutic that leverages polyphenolic compounds to exert antioxidant and anti-inflammatory effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| POMx TARGET | POMx | HaEmek Medical Center, Israel | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). POMx — Competitive Intelligence Brief. https://druglandscape.com/ci/pomx. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab